The role of platelets in bone remodeling

Inflammation and Allergy - Drug Targets

Volumn 9, Issue 5, 2010, Pages 393-399

  Sharif, Pooneh Salari ^a   Abdollahi, Mohammad ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Inflammation; Osteoporosis; Platelet derived growth factors; Platelets

Indexed keywords

COLONY STIMULATING FACTOR 1; EPIDERMAL GROWTH FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN E; PROSTAGLANDIN E2; PROSTAGLANDIN F; THROMBOXANE A2; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BONE REMODELING; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; HUMAN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; WOUND HEALING;

EID: 79751512534     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152810793938044     Document Type: Article

References (104)

1. Abdollahi, M.; Larijani, B.; Rahimi, R.; Salari, P. Role of oxidative stress in osteoporosis. Therapy, 2005, 2, 787-96.
2. Salari, P.; Larijani, B.; Abdollahi, M. Association of hyperhomocysteinemia with osteoporosis: a systematic review. Therapy, 2008, 5, 215-22.
3. Chrischilles, E.; Shireman, T.; Wallace, R. Costs and health effects of osteoporotic fractures. Bone, 1994, 15, 377-86.
4. Susa, T.; Udagawa, N.; Nakamura, I.; Miyaura, N.; Takahashi, N. Modulation of osteoclast differentiation by local factors. Bone, 1995, 17, 87S-91S.
5. Yousefzadeh, G.; Larijani, B.; Mohammadirad, A.; Heshmat, R, Dehghan, G.; Rahimi, R.; Abdollahi, M. Determination of oxidative stress status and concentration of TGF-beta 1 in the blood and saliva of osteoporotic subjects. Ann. N. Y. Acad. Sci., 2006, 1091, 142-50.
6. Yasuda, H.; Shima, N.; Nakagawa, N.; Yamaguchi, K.; Kinosaki, M.; Mochizuki, S.; Tomoyasu, A.; Yano, K.; Goto, M.; Murakami, A.; Tsuda, E; Morinaga, T.; Higashio, K.; Udagawa, N.; Takahashi, N.; Suda, T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA, 1998, 95, 3597-602.
7. Suda, T.; Takahashi, N.; Udagawa, N.; Jimi, E.; Gillespie, T.; Martin, J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev., 1999, 20, 345-57.
8. Sato, K.; Suematsu, A.; Okamoto, K.; Yamaguchi, A.; Morishita, Y.; Kadono, Y.; Tanaka, S.; Kodama, T.; Akira, S.; Iwakura, Y.; Cua, D.J.; Takayanagi, H. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med., 2006, 203, 2673-82.
9. Lorenzo, J.; Horowitz, M.; Choi, Y. Osteoimmunology: interactions of the bone and immune system. Endocr. Rev., 2008, 29, 403-40.
10. Martineau, I.; Lacoste, E.; Gagnon, G. Effects of calcium and thrombin on growth factor release from platelet concentrates: kinetics and regulation of endothelial cell proliferation. Biomaterials, 2004, 25, 4489-502.
11. Mayr-Wohlfart, U.; Waltenberger, J.; Hausser, H.; Kessler, S.; Günther, K.P.; Dehio, C.; Puhl, W.; Brenner, R.E. Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. Bone, 2002, 30, 472-7.
12. Kark, L.R., Karp, J.M.; Davies, J.E. Platelet releasate increases the proliferation and migration of bone marrow-derived cells cultured under osteogenic conditions. Clin. Oral Implants Res., 2006, 17, 321-7.
13. Sarment, D.P.; Cooke, J.W.; Miller, S.E.; Jin, Q.; McGuire, M.K.; Kao, R.T.; McClain, P.K.; McAllister, B.S.; Lynch, S.E.; Giannobile, W.V. Effect of rhPDGF-BB on bone turnover during periodontal repair. J. Clin. Periodontol., 2006, 33, 135-40.
14. Lowery, G.L.; Kulkarni, S.; Pennisi, A.E. Use of autologous factors in lumber spinal fusion. Bone, 1999, 25, 47S-50S.
15. Gruber, R.; Varga, F.; Fischer, M.B.; Watzek, G. Platelets stimulate proliferation of bone cells: involvement of platelet-derived growth factor, microparticles and membranes. Clin. Oral Implants Res., 2002, 13, 529-35.
16. Klinger, M.H.; Jelkmann, W. Role of blood platelets in infection and inflammation. J. Interferon Cytokine Res., 2002, 22, 913-22.
17. Opera, W.E.; Karp, J.M.; Hosseini, M.M.; Davies, J.E. Effect of platelet releasate on bone cell migration and recruitment in vitro. J. Craniofac. Surg., 2003,14, 292-300.
18. Rhee, J.S.; Black, M.; Schubert, U.; Fischer, S.; Morgenstern, E.; Hammes, H.P.; Preissner, K.T. The functional role of blood platelet components in angiogenesis. Thromb. Haemost., 2004, 92, 394-402.
19. Jiang, D.; Dziak, R.; Lynch, S.E.; Stephan, E.B. Modification of an osteoconductive anorganic bovine bone mineral matrix with growth factors. J. Periodontol., 1999, 70, 834-9.
20. Strayhorn, C.L.; Garret, J.S.; Dunn, R.L.; Benedict, J.J; Somerman, M.J. Growth factors regulate expression of osteoblast associated genes. J. Periodontol., 1999, 70, 1345-54.
21. Spinella-Jaegle, S.; Roman-Roman, S.; Faucheu, C.; Dunn, F.W.; Kawai, S.; Galléa, S.; Stiot, V.; Blanchet, A.M.; Courtois, B.; Baron, R.; Rawadi, G. Opposite effects of bone morphogenetic protein-2 and transforming growth factor -beta 1 on osteoblast differentiation. Bone, 2001, 29, 323-30.
22. Mott, D.A.; Mailhot, J.; Cuenin, M.F.; Sharawy, M.; Borke, J. Enhancement of osteoblast proliferation in vitro by selective enrichment of demineralized freeze-dried bone allograft with specific growth factors. J. Oral Implantol., 2002, 28, 57-66.
23. Wang, H.L.; Pappert, T.D.; Castelli, W.A.; Chiego, D.J. Jr Shyr, Y.; Smith, B.A. The effect of platelet-derived growth factor on the cellular response of the periodontium: an autoradiographic study on dogs. J. Periodontol., 1994, 65, 429-36.
24. Giannobile, W.V.; Finkelman, R.D.; Lynch, S.E. Comparison of canine and non-human primate animal models for periodontal regeneratiove therapy: results following a single administration of PDGF/IGF-I. J. Periodontol., 1994, 65, 1158-68.
25. Lind, M.; Overgaard, S.; Glerup, H.; Søballe, K.; Bünger, C. Transforming growth factor-beta1 adsorbed to tricalciumphosphate coated implants increases peri-implant bone remodeling. Biomaterials, 2001, 22, 189-93.
26. Meraw, S.J.; Reeve, C.M.; Lohse, C.M.; Sioussat, T.M. Treatment of peri-implant defects with combination growth factor cement. J. Periodontol., 2000, 71, 8-13.
27. Vuola, J.; Böhling, T.; Göransson, H.; Puolakkainen, P. Transforming growth factor beta released from natural coral implant enhances bone growth at calvarium of mature rat. J. Biomed. Mater. Res., 2002, 59, 152-9.
28. Nevins, M.; Camelo, M.; Nevins, M.L.; Schenk, R.K.; Lynch, S.E. Periodontal regeneration in humans using recombinant human platelet-derived growth factor-BB (rhPDGF-BB) and allogenic bone. J. Periodontol., 2003, 74, 1282-92.
29. Marx, R.E.; Carlson, E.R.; Eichstaet, R.M.; Schimmele, S.R.; Strauss, J.E.; Georgeff, K.R. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 1998, 85, 638-46.
30. Ogino, Y.; Ayukawa, Y.; Kukita, T.; Atsuta, I.; Koyano, K. Platelet-rich plasma suppresses osteoclastogenesis by promoting the secretion of osteoprotegerin. J. Periodontol. Res., 2009, 44, 217-24.
31. Gruber, R.; Karreth, F.; Fischer, M.B.; Watzek, G. Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanism. Bone, 2002, 30, 726-32.
32. Ogino, Y.; Ayukawa, Y.; Kukita, T.; Koyano, K. The contribution of platelet-derived growth factor, transforming growth factor-beta1 and insulin-like growth factor-I in platelet-rich plasma (PRP) to the proliferation of osteoblast-like cells. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 2006, 101, 724-9.
33. Bolander, M.E. Regulation of fracture repair by growth factors. Proc. Soc. Exp. Biol. Med., 1992, 200, 165-70.
34. Bostrom, M.P. Expression of bone morphogenetic proteins in fracture healing. Clin. Orthop. Relat. Res., 1998, 355, S116-123.
35. Claesson-Welsh, L.; Heldin, C.H. Platelet-derived growth factor. Three isoforms that bind to two distinct cell surface receptors. Acta. Oncol., 1989, 28, 331-4.
36. Tanaka, H.; Liang, C.T. Effect of platelet-derived growth factor on DNA synthesis and gene expression in bone marrow stromal cells derived from adult and old rats. J. Cell Physiol., 1995, 164, 367-75.
37. McCarthy, H.S.; Williams, J.H.; Davie, M.W.; Marshall, M.J. Platelet-derived growth factor stimulates osteoprotegerin production in osteoblastic cells. J. Cell Physiol., 2009, 218, 350-4.
38. Gawaz, M.; Langer, H.; May, A.E. Platelets in inflammation and atherogenesis. J. Clin. Invest., 2005, 115, 3378-84.
39. Endresen, G.K. Evidence for activation of platelets in the synovial fluid from patients with rheumatoid arthritis. Rheumatol. Int., 1989, 9, 19-24.
40. Chambers, T.J. Regulation of the differentiation and function of osteoclasts. J. Pathol., 2000, 192, 4-13.
41. Thirunavukkarasu, K.; Miles, R.R.; Halladay, D.L.; Yang, X.; Galvin, R.J.; Chandrasekhar, S.; Martin, T.J.; Onyia, J.E. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J. Biol. Chem., 2001, 276, 36241-50.
42. Takai, H.; Kanematsu, M.; Yano, K.; Tsuda, E.; Higashio, K.; Ikeda, K.; Watanabe, K.; Yamada, Y. Transforming growth factor- β stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J. Biol. Chem., 1998, 273, 27091-6.
43. Koseki, T.; Gaoo, Y.; Okahashi, N.; Murase, Y.; Tsujisawa, T.; Sato, T.; Yamato, K.; Nishihara, T. Role of TGF-beta family inosteoclastogenesis induced by RANKL. Cell Signal, 2002, 14, 31-6.
44. Yan, T.; Riggs, B.L.; Boyle, W.J.; Khosla, S. Regulation of osteoclastogenesis and RANK expression by TGF-beta1. J. Cell Biochem., 2001, 83, 320-5.
45. Graziani, F.; Ivanovski, S.; Cei, S.; Ducci, F.; Tonetti, M.; Gabriele, M. The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. Clin. Oral Implants Res., 2006, 17, 212-9.
46. Kanno, T.; Takabashi, T.; Tsujisawa, T.; Ariyoshi, W.; Nishibara, T. Platelet-rich plasma enhances human osteoblast-like cell proliferation and differentiation. J. Oral Maxillofac. Surg., 2005, 63, 362-9.
47. Maitz, P.; Kanndler, B.; Fischer, M.B.; Watzek, G.; Gruber, R. Activated platelets retain their potential to induce osteoclast-like cell formation in murine bone marrow cultures. Platelets, 2006, 17, 477-83.
48. Cenni, E.; Ciapetti, G.; Granchi, D.; Fotia, C.; Perut, F.; Giunti, A.; Baldini, N. Endothelial cells incubated with platelet-rich plasma express PDGF-B and ICAM-1 and induce bone marrow stromal cell migration. J. Orthop. Res., 2009, 27, 1493-8.
49. Kon, T.; Cho, T.J.; Aizawa, T.; Yamazaki, M.; Nooh, N.; Graves, D.; Gerstenfeld, L.C.; Einhorn, T.A. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. J. Bone Miner. Res., 2001, 16, 1004-14.
50. Weicht, B.; Maitz, P.; Kandler, B.; Fischer, M.B.; Watzek, G.; Gruber, R. Activated platelets positively regulate RANKLmediated osteoclast differentiation. J. Cell Biochem., 2007, 102, 1300-7.
51. Salari, P.; Mojtahedzadeh, M.; Najafi, A.; Sadraie, S.; Bahaadini, K.; Moharreri, M.; Hadavand, N.; Abdollahi, M. Comparison of the effect of aminophylline and low PEEP vs high PEEP on EGF concentration in critically ill patients with ALI/ARDS. J. Clin. Pharm. Ther., 2005, 30, 139-44.
52. Salari, P.; Mojtahedzadeh, M.; Abdollahi, M. Influence of serum epidermal growth factor on mechanical ventilation and survival in patients with acute respiratory distress syndrome. Therapy, 2005, 2, 393-8.
53. Wang, K.; Yamamoto, H.; Chin, J.R.; Werb, Z.; Vu, T.H. Epidermal growth factor receptor-deficient mice have delayed primary endochondral ossification because of defective osteoclast recruitment. J. Biol. Chem., 2004, 279, 53848-56.
54. Yi, T.; Lee, H.L.; Cha, J.H.; Ko, S.I.; Kim, H.J.; Shin, H.I.; Woo, K.M.; Ryoo, H.M.; Kim, G.S.; Baek, J.H. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling. J. Cell Physiol., 2008, 217, 409-22.
55. Saito, S.; Yamasaki, S.; Yamada, A.; Matsumoto, A.; Akatsu, T.; Takahashi, N.; Shibasaki, Y.; Suda, T.; Fukuhara, T. A stable analogue of thromboxane A2, 9,11-epithio-11,12- methanothromboxane A2, stimulates bone resorption in vitro and osteoclast-like cell formation in mouse marrow culture. Bone Miner., 1991,12, 15-23.
56. Gruber, R.; Schöfnagl, M.; Karreth, F.; Fischer, M.B.; Watzek, G. The stable analog carbocyclic TXA2 but not platelet-released TXA2 induces osteoclast-like cell formation. Prostaglandins Leukot. Essent. Fatty Acids, 2003, 68, 267-72.
57. Suzawa, T.; Miyaura, C.; Inada, M.; Maruyama, T.; Sugimoto, Y.; Ushikubi, F.; Ichikawa, A.; Narumiya, S.; Suda, T. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology, 2000,141, 1554-9.
58. Li, X.; Okada, Y.; Pilbeam, C.C.; Lorenzo, J.A.; Kennedy, C.R.; Breyer, R.M.; Raisz, L.G. Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology, 2000, 141, 2054-61.
59. Salari, P.; Rezaie, A.; Larijani, B.; Abdollahi, M. A systematic review of the impact of n-3 fatty acids in bone health and osteoporosis. Med. Sci. Monit., 2008, 14, RA37-44.
60. Salari Sharif, P.; Asalforoush, M.; Ameri, F.; Larijani, B.; Abdollahi, M. The effect of n-3 fatty acids on bone biomarkers in Iranian postmenopausal osteoporotic women: a randomized clinical trial. Age, 2010, 32, 179-86.
61. Take, I.; Kobayashi, Y.; Yamamoto, Y.; Tsuboi, H.; Ochi, T.; Uematsu, S.; Okafuji, N.; Kurihara, S.; Udagawa, N.; Takahashi, N. Prostaglandin E2 strongly inhibits human osteoclast formation. Endocrinology, 2005,146, 5204-14.
62. Salari, P.; Abdollahi, M. Controversial effects of non-steroidal antiinflammatory drugs on bone: a review. Inflamm. Allerg Drug Targets, 2009, 8, 169-75.
63. O'brien, E.A.; Williams, J.H.H.; Marshall, M.J. Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. Bone, 2001, 28, 208-14.
64. Medicherla, S.; Ma, J.Y.; Mangadu, R.; Jiang, Y.; Zhao, J.J.; Almirez, R.; Kerr, I.; Stebbins, E.G.; O'Young, G.; Kapoun, A.M.; Luedtke, G.; Chakravarty, S.; Dugar, S.; Genant, H.K.; Protter, A.A. A selective p38(alpha) MAPK inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis. J. Pharmacol. Exp. Ther., 2006, 318, 132-41.
65. Zwerina, J.; Hayer, S.; Redlich, K.; Bobacz, K.; Kollias, G.; Smolen, J.S.; Schett, G. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum., 2006, 54, 463-72.
66. Rezaie, A.; Parker, R.D.; Abdollahi, M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig. Dis. Sci., 2007, 52, 2015-21.
67. Salari, P.; Abdollahi, M. Current opinion in the pharmaceutical management of irritable and inflammatory bowel diseases: role of ATP. Recent Pat. Endocr. Metabol. Immune Drug Discov., 2009, 3, 69-75.
68. Gracia-Carrasco, M.; Mendoza-Pinto, C.; Escárcega, R.O.; Jiménez-Hernández, M.; Etchegaray Morales, I.; Munguia Realpozo, P.; Rebollo-Vázquez, J.; Soto-Vega, E.; Delezé, M.; Cervera, R. Osteoporosis in patients with systemic lupus erythematosus. Isr. Med. Assoc. J., 2009, 11, 486-91.
69. Hardy, R.; Cooper, M.S. Bone loss in inflammatory disorders. J. Endocrinol., 2009, 201, 309-20.
70. Hasani-Ranjbar, S.; Nayebi, N.; Larijani, B.; Abdollahi, M. A systematic review of the efficacy and safety of herbal medicines used in the treatment of obesity. World J. Gastroenterol., 2009, 15, 3073-85.
71. Rahimi, R.; Nikfar, S.; Larijani, B.; Abdollahi, M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed. Pharmacother., 2005, 59, 365-73.
72. Vejux, A.; Lizard, G. Cytotoxic effects of oxysterols associated with human diseases: induction of cell death (apoptosis and/or oncosis), oxidative and inflammatory activities, and phospholipidosis. Mol. Aspects. Med., 2009, 30, 153-70.
73. Gasparyan, A.Y.; Stavropoulos-Kalinoglou, A.; Mikhailidis, D.P.; Douglas, K.M. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol. Int., 2010, DOI 10.1007/s00296-010-1446-x.
74. Koh, J.M.; Khang, Y.H.; Jung, C.H.; Bae, S.; Kim, D.J.; Chung, Y.E.; Kim, G.S. Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and postmenopausal women: evidence for a link between systemic inflammation and osteoporosis. Osteoporos. Int., 2005, 16, 1263-71.
75. Scheidt-Nave, C.; Bismar, H.; Leidig-Bruckner, G.; Woitge, H.; Seibel, M.J.; Ziegler, R.; Pfeilschifter, J. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J. Clin. Endocrinol. Metab., 2001, 86, 2032-42.
76. Schoon, E.J.; Blok, B.M.; Geerling, B.J.; Russel, M.G.; Stockbrugger, R.W.; Brummer, R.J. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology, 2000, 119, 1203-8.
77. Bultink, I.E.; lems, W.F.; Kostense, P.J.; Dijkmans, B.A.; Voskuyl, A.E. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum., 2005, 52, 2044-50.
78. Momohara, S.; Okamoto, H.; Yago, T.; Furuya, T.; Nanke, Y.; Kotake, S.; Soejima, M.; Mizumura, T.; Ikari, K.; Tomatsu, T. The study of bone mineral density and bone turnover markers in postmenopausal women with active rheumatoid arthritis. Mod. Rheumatol., 2005, 15, 410-4.
79. Fournier, C. Where do T cells stand in rheumatoid arthritis? Joint Bone Spine, 2005, 72, 527-32.
80. Ogawa, Y.; Ohtsuki, M.; Uzuki, M.; Sawai, T.; Onozawa, Y.; Nakayama, J.; Yonemura, A.; Kimura, T.; Matsuno, H. Suppression of osteoclastogenesis in rheumatoid arthritis by induction of apoptosis in activated CD4+ T cells. Arthritis Rheum., 2003, 48, 3350-8.
81. Rifas, L. T-cell cytokine induction of BMP-2 regulates human mesenchymal stromal cell differentiation and mineralization. J. Cell Biochem., 2006, 98, 706-14.
82. Rifas, L.; Arackal, S.; Weitzmann, M.N. Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts. J. Cell Biochem., 2003, 88, 650-9.
83. Diarra, D.; Stolina, M.; Polzer, K.; Zwerina, J.; Ominsky, M.S.; Dwyer, D.; Korb, A.; Smolen, J.; Hoffmann, M.; Scheinecker, C.; van der Heide, D.; Landewe, R.; Lacey, D.; Richards, W.G.; Schett, G. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med., 2007, 13, 156-63.
84. Klinger, M.H. Platelets and inflammation. Anat. Embryol., 1997, 196, 1-11.
85. Rex, S.; Beaulieu, L.M.; Perlman, D.H.; Vitseva, O.; Blair, P.S.; McComb, M.E.; Costello, C.E.; Freedman, J.E. Immune versus thrombotic stimulation of platelets differentially regulates signaling pathways, intracellular protein-protein interactions, and alphagranule release. Thromb. Haemost., 2009, 102, 97-110.
86. Langer, H.F.; Gawaz, M. Platelet-vessel wall interactions in atherosclerotic disease. Thromb. Haemost., 2008, 99, 480-6.
87. Libby, P.; Ridker, P.M.; Maseri, A. Inflammation and atherosclerosis. Circulation, 2002, 105, 1135-43.
88. Ruggeri, Z.M. Platelets in atherothrombosis. Nat. Med., 2002, 8, 1227-34.
89. Opal, S.M.; Esmon, C.T. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit. Care, 2003, 7, 23-38.
90. Yan, Z.Q.; Hansson, G.K. Innate immunity, macrophage activation, and atherosclerosis. Immunol. Rev., 2007, 219, 187-203.
91. Boilard, E.; Nigrovic, P.A.; Larabee, K.; Watts, G.F.; Coblyn, J.S.; Weinblatt, M.E.; Massarotti, E.M.; Remold-O'Donnell, E.; Farndale, R.W.; Ware, J.; Lee, D.M. Platelets amplify nflammation in arthritis via collagen-dependent microparticle production. Science, 2010, 327, 580-3.
92. Teichman, J.; Lange, U.; Stracke, H.; Federlin, K.; Bretzel, R.G. Bone metabolism and bone mineral density of systemic lupus erythematosus at the time of diagnosis. Rheumatol. Int., 1999, 18, 137-40.
93. Alele, J.D.; Kamen, D.L. The importance of inflammation and vitamin D status in SLE-associated osteoporosis. Autoimmun. Rev., 2010, 9, 137-39.
94. Zaiss, M.M.; Axmann, R.; Zwerina, J.; Polzer, K.; Gükel, E.; Skapenko, A.; Schulze-Koos, H.; Horwood, N.; Cope, A.; Schett, G. Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum., 2007, 56, 4104-12.
95. Judge, H.M.; Buckland, R.J.; Sugidachi, A.; Jakubowski, J.A.; Storey, R.F. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and proinflammatory platelet responses. Platelets, 2008, 19, 125-33.
96. Gasparyan, A.Y.; Watson, T.; Lip, G.Y. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J. Am. Coll. Cardiol., 2008, 51, 1829-43.
97. Evangelista, V.; Manarini, S.; Dell'Elba, G.; Martelli, N.; Napoleone, E.; Di Santo, A.; Lorenzet, P.S. Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation. Thromb. Haemost., 2005, 94, 568-77.
98. Ayral, Y.; Rauch, U.; Goldin-Lang, P.; Stellbaum, C.; Deiner, C.; Schwimmbeck, P.L.; Schultheiss, H.P.; Pels, K. Prolonged application of clopidogrel reduces inflammation after percutaneous coronary intervention in the porcine model. Cardiovasc. Revasc. Med., 2007, 8, 183-8.
99. Egan, K.M.; Wang, M.; Fries, S.; Lucitt, M.B.; Zukas, A.M.; Puré, E.; Lawson, J.A.; FitzGerald, G.A. Cyclooxygenas, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation, 2005, 111, 334-42.
100. Solheim, S.; Pettersen, A.A.; Arnesen, H.; Seljeflot, I. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. Thromb. Haemost., 2006, 96, 660-4.
101. Solheim, S.; Arnesen, H.; Eikvar, L.; Hurlen, M.; Seljeflot, I. Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. Am. J. Cardiol., 2003, 92, 843-5.
102. Li, N.; Hu, H.; Hjemdahl, P. Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry. Thromb. Res., 2003, 111, 165-70.
103. Muhlestein, J.B. Effect of antiplatelet therapy on inflammatory markers in atherosclerotic patients. Thromb. Haemost., 2010, 103, 71-82.
104. Klinkhardt, U.; Bauersachs, R.; Adams, J.; Graff, J.; Lindhoff-Last, E.; Harder, S. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin. Pharmacol. Ther., 2003, 73, 232-41.